What is B. Riley’s Estimate for TG Therapeutics Q4 Earnings?

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley raised their Q4 2025 earnings estimates for TG Therapeutics in a note issued to investors on Monday, August 4th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $0.36 per share for the quarter, up from their prior forecast of $0.34. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.34 EPS, FY2027 earnings at $2.38 EPS, FY2028 earnings at $3.52 EPS and FY2029 earnings at $4.42 EPS.

Separately, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price target for the company in a research report on Thursday, July 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.80.

TG Therapeutics Stock Down 2.5%

TG Therapeutics stock opened at $27.70 on Wednesday. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. The firm has a market cap of $4.40 billion, a P/E ratio of 74.86 and a beta of 1.95. The business has a fifty day moving average of $36.42 and a two-hundred day moving average of $35.99. TG Therapeutics has a twelve month low of $19.44 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. TG Therapeutics’s revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.04 earnings per share.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in TGTX. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at approximately $25,000. NBC Securities Inc. increased its stake in TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 823 shares in the last quarter. Golden State Wealth Management LLC increased its stake in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 433 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of TG Therapeutics in the first quarter worth $37,000. Finally, Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $30,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the company’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director directly owned 228,816 shares of the company’s stock, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 10.64% of the stock is owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.